Edoxaban vs. warfarin in vitamin K antagonist experienced and naive patients with atrial fibrillation†

Patterns of Initiation of Oral Anticoagulants in Patients with Atrial Fibrillation— Quality and Cost Implications

(2014) Nihar R. Desai et al.   AMERICAN JOURNAL OF MEDICINE

Apixaban versus warfarin in patients with atrial fibrillation according to prior warfarin use: Results from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation trial

(2013) David A. Garcia et al.   AMERICAN HEART JOURNAL

Clinical Outcomes With Rivaroxaban in Patients Transitioned From Vitamin K Antagonist Therapy

(2013) Kenneth W. Mahaffey et al.   ANNALS OF INTERNAL MEDICINE

Edoxaban versus Warfarin in Patients with Atrial Fibrillation

(2013) Robert P. Giugliano et al.   NEW ENGLAND JOURNAL OF MEDICINE

2012 focused update of the ESC Guidelines for the management of atrial fibrillation

(2012) et al.   EUROPEAN HEART JOURNAL

Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: Design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation–Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF–TIMI 48)

(2010) Christian T. Ruff et al.   AMERICAN HEART JOURNAL

Dabigatran and Warfarin in Vitamin K Antagonist–Naive and –Experienced Cohorts With Atrial Fibrillation

(2010) Michael D. Ezekowitz et al.   CIRCULATION

Benefit of Oral Anticoagulant Over Antiplatelet Therapy in Atrial Fibrillation Depends on the Quality of International Normalized Ratio Control Achieved by Centers and Countries as Measured by Time in Therapeutic Range

(2008) Stuart J. Connolly et al.   CIRCULATION

Disparate Stroke Rates on Warfarin Among Contemporaneous Cohorts With Atrial Fibrillation

(2008) Elaine M. Hylek et al.   STROKE